Mesothelioma May be Combated With Viruses
Posted on Tuesday, June 28, 2011.

mesothelioma gene therapyThey are typically thought of as a cause of illness, but viruses may also be an important key to fighting the asbestos-linked cancer, mesothelioma. Medical researchers in Japan are using viruses to deliver information directly into mesothelioma cells in mice that can help the cells respond better to cancer-fighting medication. 

The researchers first tested their approach to gene therapy in test tubes, delivering genetic information to mesothelioma cells using modified viruses called retroviruses. In the past, scientists primarily used retroviruses that were unable to replicate themselves, to ensure that the replication process did not get out of control. But for their recent experiments, the Japanese team used replicable viruses – called replication-competent (RCR) viruses – instead.

While it is considered a riskier approach, using replication-competent viruses is also thought to be more effective because they can help get the key genes into more cells. This was the case in the Japanese study. The team reports that the marker gene “successfully infected and efficiently replicated” in human malignant mesothelioma cell lines in vitro without affecting non-malignant mesothelial cells.

Next, the researchers tried the same experiment in live subjects.  When the replication-competent retrovirus was injected into the tumors of mesothelioma-infected mice, it showed “robust spread” and “efficient transmission” of the prodrug activator gene throughout entire tumor masses.  The infected tumors were then treated with an anti-fungal drug called 5-fluorocytosine, which interferes with the building of certain essential proteins.

In a recent report of their findings in the journal Cancer Gene Therapy, the researchers say the process resulted in “significant inhibition” of tumor growth and “significantly prolonged survival” in mice with peritoneal mesothelioma.  They write, “These data indicate the potential utility of RCR vector-mediated prodrug activator therapy in the treatment of malignant mesothelioma.”

Gene therapy is a promising new area of research for mesothelioma, a rare but incurable disease that is caused by exposure to the mineral asbestos. Its fast growth, drug resistance, and irregular tumor shape tend to make mesothelioma difficult to treat with conventional therapies.

Sources:

Kawasaki, Y et al, “Replication-competent retrovius vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma”, June 10, 2011, Cancer Gene Therapy, Epub ahead of print.
Hiraoka, K, “Therapeutic efficacy of replicaion-competent retrovirus vctor-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model”, June 1, 2007, Cancer Research, pp. 5345-53.
 
 
 
© Surviving Mesothelioma and Cancer Monthly. All rights reserved.
 
 
 




DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.